Plasma MiRNA alterations between NSCLC patients harboring Del19 and L858R EGFR mutations

Based on recognition of driver mutations, treatment paradigm for non-small-cell lung cancer (NSCLC) patients has been shifted. However, recently exon 19 deletion mutation (del19) of epidermal growth factor receptor (EGFR) clearly shows better clinical benefit over single-point substitution mutation...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Yihan, Xu, Peiqi, Mi, Yanjun, Wang, Wenyi, Pan, Xiaoyan, Wu, Xiaoting, He, Qi, Liu, Hongming, Tang, Weiwei, An, Hanxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342394/
https://www.ncbi.nlm.nih.gov/pubmed/27463019
http://dx.doi.org/10.18632/oncotarget.10829

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342394/
https://www.ncbi.nlm.nih.gov/pubmed/27463019
http://dx.doi.org/10.18632/oncotarget.10829

Ejemplares similares